StudyFinder

A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult atypical hemolytic uremic syndrome (aHUS) patients who are naive to complement inhibitor therapy

Status: Recruiting

To evaluate the efficacy and safety of iptacopan at a dose of 200 mg twice a day for 52 weeks in patients with atypical hemolytic uremic syndrome (aHUS).

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• evidence of active Thrombotic Microangiopathy (TMA)
Exclusion Criteria:

• previous or ongoing treatment with complement inhibitors, including anti-C5 antibody
• ADAMTS13 deficiency
• positive test for Shiga toxin * direct Coombs test
• had a bone marrow transplant or hematopoietic stem cell transplant, or a heart, lung, small bowel, pancreas or live transplant
Conditions:

Blood Disorders, Kidney, Prostate & Urinary, Rare Diseases

Keywords:

Clinics and Surgery Center (CSC)

Study Contact: Nattawat Klomjit - klomj001@umn.edu
Principal Investigator: Nattawat Klomjit
Phase: PHASE3
IRB Number: STUDY00020503
See this study on ClinicalTrials.gov

Back